Health Catalyst, Inc. (NASDAQ:HCAT) COO Sells $40,005.12 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur sold 5,209 shares of the stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total transaction of $40,005.12. Following the sale, the chief operating officer now owns 134,899 shares in the company, valued at approximately $1,036,024.32. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Daniel Lesueur also recently made the following trade(s):

• On Wednesday, September 4th, Daniel Lesueur sold 8,137 shares of Health Catalyst stock. The stock was sold at an average price of $7.58, for a total value of $61,678.46.
• On Monday, August 5th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The stock was sold at an average price of $6.19, for a total value of $32,243.71.

Health Catalyst Price Performance

NASDAQ HCAT opened at $7.85 on Friday. The company has a fifty day moving average of $7.45 and a two-hundred day moving average of $6.89. Health Catalyst, Inc. has a 1 year low of $5.42 and a 1 year high of $11.41. The company has a market capitalization of $463.42 million, a PE ratio of -4.24 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.04. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The firm had revenue of $75.90 million for the quarter, compared to the consensus estimate of $74.96 million. During the same quarter last year, the business posted ($0.21) EPS. The firm’s quarterly revenue was up 3.7% compared to the same quarter last year. On average, research analysts expect that Health Catalyst, Inc. will post -0.35 earnings per share for the current year.

Analysts Set New Price Targets

HCAT has been the subject of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a research note on Friday, October 4th. Stephens decreased their price target on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research note on Thursday, August 8th. Evercore ISI increased their price objective on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday. Piper Sandler reduced their price objective on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, August 26th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.58.

Hedge Funds Weigh In On Health Catalyst

A number of institutional investors have recently modified their holdings of the business. Nisa Investment Advisors LLC grew its position in Health Catalyst by 461.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after purchasing an additional 5,232 shares during the last quarter. Quarry LP boosted its stake in shares of Health Catalyst by 59.4% during the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after buying an additional 2,610 shares during the period. Perfromance Wealth Partners LLC acquired a new stake in shares of Health Catalyst during the second quarter worth about $64,000. Mackenzie Financial Corp purchased a new position in shares of Health Catalyst during the second quarter worth about $70,000. Finally, EntryPoint Capital LLC acquired a new position in Health Catalyst in the 1st quarter valued at about $98,000. 85.00% of the stock is owned by institutional investors and hedge funds.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.